Delivery Order SPE2DB25D3012-SPE2DB25FXABH
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $4,540.96 to AmerisourceBergen Drug Corp for the supply of Armodafinil 250 mg tablets (30-count units) on September 16, 2025, with completion scheduled for September 17, 2025. This non-competitive, firm fixed-price delivery order represents a routine pharmaceutical procurement supporting federal medical supply needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Armodafinil 250 mg tablets (30-count units) under a firm fixed-price contract valued at $2,458.96. The award, issued on August 12, 2025, with an ultimate completion date of August 13, 2025, represents a non-competitive delivery order with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This...
- The Defense Logistics Agency awarded a delivery order valued at $2,199.45 to AmerisourceBergen Drug Corp for the supply of Armodafinil 250 mg tablets (30-count units) on August 13, 2025, with completion scheduled for August 14, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,115.00 to AmerisourceBergen Drug Corp for Armodafinil 250 mg tablets (30-count packages) on July 30, 2025, with an ultimate completion date of July 31, 2025. This firm fixed price, non-set-aside contract will be performed at the vendor's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $1,779.24 to AmerisourceBergen Drug Corp for Armodafinil 250 mg tablets (30-count units) on July 25, 2025, with an ultimate completion date of July 28, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle. The product will be delivered to the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $1,672.50 to AmerisourceBergen Drug Corp for Armodafinil 250 mg tablets (30-count supply) on July 23, 2025, with an ultimate completion date of July 24, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation and will be performed at the contractor's location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for federal...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Armodafinil 250 mg tablets in quantities of 30 units. This firm fixed-price delivery order, valued at $2,863.95, was competitively awarded without set-aside designation and is scheduled for completion by August 26, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the...
- The Defense Logistics Agency awarded a $1,672.35 delivery order to AmerisourceBergen Drug Corp on July 10, 2025, for the supply of Armodafinil 250 mg tablets in quantities of 30 units. This is a firm fixed price contract with an ultimate completion date of July 11, 2025, and represents a non-competitive set-aside award. The contract is performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters as a leading pharmaceutical...
- The Defense Logistics Agency has awarded a delivery order valued at $2,401.31 to AmerisourceBergen Drug Corp for the supply of Armodafinil 250 mg tablets in quantities of 30 units. This firm fixed-price delivery order was competitively awarded with no set-aside designation and is scheduled for completion by June 20, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $2,927.46 by the Defense Logistics Agency on July 15, 2025, for the supply of Armodafinil 250 mg tablets in quantities of 30. The contract carries a firm fixed price structure with no set-aside designation, indicating competitive award through open procurement. This delivery order is a child contract under AmerisourceBergen's substantial Indefinite...
- SPE2DB25D3012Indefinite Delivery Contract
- SPE2DB25D3012-SPE2DB25FXABHDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,476.51 to AmerisourceBergen Drug Corp for the supply of Armodafinil 250 mg tablets (30-count units) on September 15, 2025, with a completion date of September 16, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.9 billion comprehensive pharmaceutical support vehicle running through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal military and veteran healthcare systems. The contractor's extensive portfolio with the DLA encompasses a wide range of pharmaceutical products and medical supplies, including specialty medications, generic and brand-name drugs, vaccines, and medical devices across multiple therapeutic domains. The company's ability to fulfill this delivery order reflects its established capability to meet federal procurement requirements through open competition and its significant role within the DLA's global pharmaceutical supply chain supporting the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.5k | 9/15/25 |